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Introduction: Safe, effective and consistent tight glycemic control (TGC) has been difficult to achieve. STAR (Stochastic TARgeted) is a flexible, model-based TGC approach that directly accounts for intra- and inter- patient variability with a stochastically derived maximum 5% risk of blood glucose (BG) below 4.4mmol/L. This research assesses the safety and efficacy of STAR.

Method: Seven patients (660hrs), controlling insulin and nutrition interventions are calculated using clinically validated computer models of human metabolism and its variability in critical illness 1-3 hourly. Nurses choose the interval (1-3hours) to manage workload. Interventions maximize the overlap of model-predicted (5-95%-tile) range of BG outcomes with the 4.4-6.5mmol/L band, guaranteeing a maximum 5% risk of BG<4.4mmol/L. Insulin doses (8U/hour) and dose change (+2U/hour) are limited All measurements were taken with bedside glucometers.

Results are compared to SPRINT (current standard). Written informed consent was obtained for all patients (NZ Upper South A Regional Ethics Committee).

Results: 402 measurements were made (~14/day). Nurses showed a preference for 2-hourly measurements (<10 3-hourly intervals chosen). Median [IQR] cohort BG was 5.9 [5.2-6.8]mmol/L. Overall, 72%, 86% and 95% of measurements were in 4.0-6.5mmol/L, 4.0-7.0mmol/L and 4.0-8.0mmol/L bands. Minimum BG was 3.5mmol/L with 4.8% <4.4mmol/L. 

Per-Patient median [IQR] hours of TGC was 92 [29-113]hours using 53 [19-62] measurements (~13.5/day median). Per-patient median results were: BG, 5.9 [5.8-6.3]mmol/L; Carbohydrate Administered, 6.8 [5.5-8.7]g/hour (~70% ACCP goal); Insulin, 2.5 [0.1-5.1]U/hour. All patients achieved BG<6.1mmol/L.

For comparison, the SPRINT cohort BG was 5.7 [5.0-6.6]mmol/L, and per-patient median BG was 5.8 [5.3-6.4]mmol/L, with a 2% (by patient) rate of hypoglycemia.

Conclusion: STAR TGC modulating insulin and nutrition inputs provided safe, effective TGC exceeding SPRINT, which reduced cost and mortality, by model-based management of intra- and inter- patient variability. Using glucometers did not impact TGC quality. Clinical workload was self-managed and reduced 20% versus SPRINT. 


